Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would think one would be more concerned with the steady decline of MONI and what THAT CEO is doing (or not doing) than focusing on the CEO of a previous investment. MONI share price has steadily declined over the last several months and is lower than TOMDF share price. Yikes!!
How long will it be before the sentiment towards Alison turns sour? Go GIRL POWER!!! LMAO
Personally, I give it another 4-6 months and the rats will start jumping off the sinking MONI ship.
But I get it... vast riches just around the corner for those who understand what's going on behind the scenes. Deep Wall Street roots and all. Same old lame story. Perhaps it's time for a CTJ talk with Alison so the whales can be rallied to pump up the MONI share price... currently below 0.04 and headed for 0.03 soon.
Still time to buy AMBS and TOMDF shares before phase 2 interim results announced. Fully loaded here in Todos, and won't have to hold for a decade to turn a profit. AMBS will benefit as well due to their 78M shares of TOMDF.
Cheddar News VIDEO Link
"There's no doubt there's going to be a significant increase in cases": @G_Commish says there will likely be a surge in COVID-19 cases in the US over the upcoming holidays. pic.twitter.com/jIp84nppvG
— Cheddar (@cheddar) November 18, 2021
NEWS: Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test
· Reauthorization of EUA expands beyond initial qualitative detection claim
· CEO to appear on Cheddar News at 6:10pm tonight, November 17th, 2021
New York, NY, and Tel Aviv, ISRAEL, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the United States Food & Drug Administration has reauthorized the Emergency Use Authorization (EUA) for the cPass neutralizing antibody test (“cPass”)*. The new indication for cPass now reads:
Qualitative and semi-quantitative direct detection of total neutralizing antibodies to SARS-CoV-2 in human serum and dipotassium EDTA plasma. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories.
Concurrent with this announcement, the Company announced that CEO Gerald Commissiong is to appear on Cheddar News at 6:10pm tonight, November 17th, 2021.
For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.
* This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the presence of total neutralizing antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
https://investor.todosmedical.com/news-events/press-releases/detail/151/todos-medical-announces-addition-of-semi-quantitative-titer
NEWS: Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests
https://investor.todosmedical.com/news-events/press-releases/detail/149/todos-medicals-provista-laboratory-to-boost-top-line
New York, NY, and Tel Aviv, ISRAEL, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its wholly-owned CLIA/CAP laboratory Provista Diagnostics has entered into a new reference lab agreement with an Atlanta-based CLIA laboratory (the “New Client”). Provista will be providing COVID PCR, cPass Neutralizing Antibody and Respiratory Pathogen Panel (RPP) testing with local sample collection expected to yield less than 12-hour turnaround times. The Company expects to initially add 2,000 COVID PCR tests monthly, and increase the overall production on a monthly basis. Due to the steadily increasing demand for combined COVID and RPP testing for symptomatic pediatric patients, Provista’s highly automated systems provide for quick turnaround time making it uniquely positioned to meet the demands of this lab and others seeking these reference services. Fast and accurate testing can determine the most effective course of treatment. This year many in the industry are expecting a harsh cold and flu season. Additionally, the New Client already services skilled nursing and long-term care facilities that are looking to add the cPass neutralizing antibody testing into their health & safety protocols for residents and staff.
“Business development at Provista is in a pronounced upswing. We see it in the increased throughput and the increasing sales pipeline,” said Gerald E. Commissiong, President & CEO for Todos Medical & Provista. “This momentum at Provista is exactly what we need to energize the business, as we expect this will be the first of many reference lab agreements for whom we can deliver high throughput testing with very fast and clinically relevant turnaround times. Our sales team is positioning our excess testing capability extremely well and it’s resonating with prospects. As we move into the holiday traveling season with falling temperatures that lead people indoors, the PCR COVID, cPass, and RPP testing panel have become critically important tests. This reference agreement could potentially drive millions to our top line, and provide further validation for other reference lab clients of our ability to deliver. Additionally, these testing options should make a big difference in our community to maximize safety for the holidays.”
NPR: How SARS-CoV-2 in American deer could alter the course of the global pandemic
November 10, 2021
Link below includes 3-Minute audio.
https://www.npr.org/sections/goatsandsoda/2021/11/10/1054224204/how-sars-cov-2-in-american-deer-could-alter-the-course-of-the-global-pandemic?utm_medium=social&utm_source=twitter.com&utm_campaign=npr&utm_term=nprnews
Scientists have evidence that SARS-CoV-2 spreads explosively in white-tailed deer and that the virus is widespread in this deer population across the United States.
Researchers say the findings are quite concerning and could have vast implications for the long-term course of the coronavirus pandemic.
Since SARS-CoV-2, the coronavirus that causes the disease COVID-19, first emerged, there have been several signs that white-tailed deer would be highly susceptible to the virus — and that many of these animals were catching it across the country.
In September of last year, computer models suggested SARS-CoV-2 could easily bind to and enter the deer's cells. A recent survey of white-tailed deer in the Northeast and Midwest found that 40% of them had antibodies against SARS-CoV-2.
Now veterinarians at Pennsylvania State University have found active SARS-CoV-2 infections in at least 30% of deer tested across Iowa during 2020. Their study, published online last week, suggests that white-tailed deer could become what's known as a reservoir for SARS-CoV-2. That is, the animals could carry the virus indefinitely and spread it back to humans periodically.
If that's the case, it would essentially dash any hopes of eliminating or eradicating the virus in the U.S. — and therefore from the world — says veterinary virologist Suresh Kuchipudi at Penn State, who co-led the study.
"If the virus has opportunities to find an alternate host besides humans, which we would call a reservoir, that will create a safe haven where the virus can continue to circulate even if the entire human population becomes immune," he says. "And so it becomes more and more complicated to manage or even eradicate the virus."
In the study, Kuchipudi and his colleagues looked for the presence of the SARS-CoV-2 virus in the lymph nodes of nearly 300 white-tailed deer, including more than 100 wild deer. "So these deer were either roadkill or free-living deer that hunters had killed [to eat]," says veterinary microbiologist Vivek Kapur at Penn State, who also co-led the study.
What they found left Kapur and Kuchipudi dumbfounded. "It was actually quite stunning to us," Kapur says. "We were very surprised to see such a high number of positive samples."
From April to December of last year, about 30% of the deer that they tested were positive for SARS-CoV-2 by a PCR test. And then during the winter surge in Iowa, from Nov. 23, 2020, to Jan. 10 of this year, about 80% of the deer that they tested were infected. At the peak of the surge, Kapur says, the prevalence of the virus in deer was effectively about 50 to 100 times the prevalence in Iowa residents at the time.
During this time frame, the team also sequenced the genes of nearly 100 samples of the virus. They found the variants circulating in the deer matched the variants circulating in people.
Those genomic sequences suggest that during the pandemic, deer have caught the virus from people multiple times in Iowa alone, Kapur says. "The data are very consistent again with frequent spillover events from humans into deer and then transmission among the animals."
Virologist Linda Saif at Ohio State University's College of Veterinary Medicine says humans are likely infecting white-tailed deer across the country. The white-tailed deer is native to North America, Central America and the northern edge of South America. In the U.S. alone, there are an estimated 30 million animals.
"We also have detected the virus in deer in Ohio," she says. "And there are antibody studies that suggest the prevalence of COVID infections among deer are pretty high in the Midwest and East."
Although the virus doesn't seem to make the animals sick, Saif says, the new data from Iowa are "very concerning."
"Now the question is: Can the virus spill back from deer to humans? Or can deer transmit the virus effectively to grazing livestock? We don't know the answers to those questions yet, but if they are true, they're obviously concerning," she says.
Another concern, Saif says, is that SARS-CoV-2 could evolve inside the deer and create new strains of the virus. Researchers have already documented such a scenario with minks on farms in the Netherlands and Poland, she points out.
In those studies, farmworkers passed the virus on to captive animals. As the virus spread through the minks, it mutated and created new variants. These new versions of the virus then spilled back to the humans, the researchers reported.
At the end of day, tracking the emergence of new variants may become much more complicated, says Kuchipudi.
"If we want to continue to be proactive about emerging variants — and not be surprised by one that suddenly pops up — there's an urgent need to continue to monitor SARS-CoV-2 in wildlife," he says, "especially in animals that could serve as a reservoir, like the deer."
Seeking Alpha: Merck's Plan B Percolates After Pfizer Announces Dominance
Great read.
https://seekingalpha.com/article/4469170-mercks-mark-plan-b-percolates-after-pfizer-announces-dominance
Share Structure Update - 11/12/21
No change in outstanding shares from last week.
https://www.otcmarkets.com/stock/TOMDF/security
I hope it turns out to be a smart move. The potential rewards here are fantastic, but risk level is still high, although it seems less risky as we get closer to data release.
If your 401k allows it, you can contribute after-tax and roll those contributions to a Roth IRA where the investment gains and withdrawals are never taxed. One can move $60K+ per year to a Roth IRA this way, which greatly exceeds the limited annual contribution amount.
Me and several of my coworkers are using this strategy because our 401k allows it. Not all 401k plans do. Search for "Mega-Backdoor Roth IRA" for details. Great option if your plan allows it and you have the means to increase contributions. One of the biggest reasons I became debt-free was to fund my Roth IRA this way. The potential Roth balances with good investments and maximizing contributions this way is enormous, far greater than you could achieve with annual contributions alone. That's my retirement play and now Todos is a part of the investments in that account.
Just ordered a bottle of Tollovid at the current price. Looking forward to seeing the sales numbers in the upcoming 10-Q, although I expect the biggest increase in sales won't be seen until 4th quarter and beyond.
I'm sure there are synergies. I'm just an investor (more a speculator since this is OTC penny stock), so what do I know? Agreed, exciting months ahead. Loaded for BEAR with TOMDF in multiple accounts, with majority of shares in tax-free Roth IRA and HSA accounts, so looking forward to seeing those account balances climb skyward. GLTY
I don't see Tollovid going to Amarantus since Amarantus is not part of Todos Medical. To spin off Tollovid into a subsidiary, Todos would have to acquire Amarantus first. I don't see that happening.
Gerald has hinted that with the 78M Todos shares owned by Amarantus, with the Tollovir data release and subsequent uplisting and partnership potential, Todos share price would allow Amarantus to sell their Todos shares, pay off all debt, and have plenty fo capital to fund multiple trials for MANF, their crown jewel asset. That seems to be the plan for reviving Amarantus.
Of course, things may change. Everything in the near future is dependent on the Tollovir data, but from the in-depth articles and observation data already published, it appears we have a winner.
Tollovid price increases on Monday, November 15, 2021
Just received this email notification from Todos Medical. Gerald previously stated the price of the maximum strength Tollovid would be increasing. Now it's happening.
Demand must be better than anticipated. Business 101... if demand is significantly higher than expectations, your price is too low. This is the second price increase for Tollovid, starting at $135, then raised to $199, and being raised again to $349. I guess that's the result of being the ONLY 3CL Protease Inhibitor available in the market. As more people read and understand the mechanism of the protease inhibitor on coronavirus replication, they want the only inhibitor available. FDA approval certainly raises the perception of product safety.
If you buy before the price increase, don't forget to use the IMMUNITY10 discount code for 10% off... bringing the current price to $179.10.
Again, Tollovid Daily price remains unchanged, and the subscription price is 10% lower than the single bottle price, but the discount code also works for the single bottle.
In the Sequire Spotlight video I just posted, Gerald made a statement starting at 9:10 they intend to put the 3CL protease inhibitor products into a subsidiary that will be self-funded so the company can focus on the diagnostic assets while still controlling the subsidiary.
It appears their strategy has changed as more data has come in. In my mind, the decision to keep the 3CL products in a subsidiary could be the result of several possibilities.
1. Big pharma has shown little or no interest in partnering or a buyout. I doubt this one is valid since Gerald has stated multiple times there is interest from multiple potential partners.
2. Demand for product and revenue projections have driven the company to want to keep all the revenue and profits instead of sharing it with a partner or selling it for short-term gain while long-term potential is greater. Big pharma would always want to acquire the assets for less than the future potential revenue in order to make a profit on the purchase. Why sell or partner when you can enjoy the whole pie?
3. Big pharma has shown significant interest in partnering or possible buyout and by announcing intent to keep the 3CL assets in a subsidiary controlled by the company, the cost to partner or acquire the assets could be significantly higher. The decision to move assets into a subsidiary shows the company realizes the full market potential and has decided to maintain ownership and control the assets. Perhaps the company now actually plans to keep the assets, or this is a strategy to increase level of competitive bidding by competitors for the assets.
Thoughts or alternative opinions are appreciated. Exciting times ahead for Todos shareholders, and I recommend everyone keep things in perspective. This may not happen as fast as we desire. A number of things still need to go well and in the right order for this to impact the share price. I expect to see significant moves upward in share price coupled with significant short-term declines as investors sell to take profits. Could be a bumpy ride as things unfold. GLTA
He would have to find us first. LOL Hoping Rayn_Makr will reply and provide more insight into what we're missing. Maybe the reference is to the World Health Organization?
I also thought the reference might be to federal government. I mean, what's bigger than "big pharma"? But then I ask myself why they would go with Todos when likely all of their personal investments were in big pharma, so the motivation would be to assign the big government contracts to those companies they would personally benefit from. I can't see them taking an interest in Todos as they likely have no investment here. Sad to think government bureaucrats would put their personal financial interests ahead of the safety of the population, but the reality is that's how the world works. Believing their top priority is the welfare of the American people and going with the most effective treatment with the best safety profile is an illusion, IMHO.
Sorry, I'm not making the connection. Could you elaborate more on your post? What is the perfect fit that is better than a big pharma buyout or partnership?
And the bigger question is... why is that all you can say?
I like the sound of that. And a potential buyout offer should be based on revenue potential for Tollovir/Tollovid, not the current share price of the company. A buyout offer of $1 or $2 per share would seem like a fantastic win for shareholders, but it would be a low-ball bid based on market potential of the most effective antiviral tested thus far for COVID-19, including all variants to come.
Question is, would the company sell just the antiviral product, or the entire company? Multiple bidders and a bidding war possible? Or perhaps just a partnership where Todos maintains control and ownership of the IP, and big pharma handles the distribution and government contracts, etc.
Hopefully we may have an answer by end of 2021, but realistically I'm setting my expectations to Q1 or Q2 of 2022. Still buying.
Fair point. I didn't pay enough attention to the plot to realize IHUB only plots the MONI performance, not the prior WOGI performance.
Okay, here's honest for ya... I bought WOGI/MONI several times starting in May 2021, which is 6 months ago and based on your recommendation. I took a look at it and it seemed to have some potential based on what was being shared on the boards, but except for a short-lived run-up where I should have unloaded my shares, it's been relatively flat... no better than Todos performance.
I'll show the performance of the stock since my initial purchase, because that's the only timeline that matters to me. If I had sold my initial purchase in the summer run-up I might have a profit, but I held because of the pumping on the MONI board (including yours) about it going much higher, and holding it has made it nothing but a turd for me. "Girl Power"... LMAO. I hope it turns out well for you, but unlike you I haven't been invested in WOGI/MONI for the last decade, and over that time you've made many posts touting what was "just around the corner". I've also seen posts where you bought at much higher prices than the current price. For my timeline it's a turd. I'm better off in Todos shares. I like the potential of Todos better and have built a sizable position over the last 6 months.
Good luck to you in MONI, but I'm betting on the horse named Tollovir. With positive data coming soon, I expect the buyout offers from big pharma will send the share price much higher.
Agreed, seems like much less of a gamble than a couple of months ago. I was referring to the penny stock status as a gamble. Amarantus was a gamble for many and that didn't work out so well. I believe GC has learned from those lessons and will succeed here. Hopefully that will drive renewed interest in Amarantus and restart of those asset programs. MANF and ESS certainly need to be moved forward.
I'm continuing to buy Todos through end of year, although I already have acquired the bulk of the Todos shares I will own. Good luck. Exciting times ahead.
Watch some of those constantly trashing the stock and CEO start posting more positively when the data is released and share price moves much higher... as though they are very knowledgeable of all things antiviral and have been following the science closely all along. We might see claims they bought shares so not to appear to be left out of the success we'll be enjoying. They will claim they would never pass up an opportunity like Todos, even if it means investing with a con artist CEO and pathological liar who deserves to be in prison (their opinion posted many times here). It will certainly provide lots of entertainment for many of us.
That being said, I realize this is a gamble on our part, but also an amazing opportunity at these prices if the science and decades of 3CL protease research done at NLC Pharma can be monetized in the market. It will be an amazing next few weeks and months.
Pinch? Are you kidding? I've used the declining share price to my advantage as the improving story unfolds. Just because most have never heard of Todos or don't understand what's about to happen here doesn't mean I'm stressed. Just the opposite. I've moved in additional funds to buy shares. Loaded for bear now.
My Todos average price is 0.0686 and heading lower this week as I buy more shares. Sold my shares in that MONI turd you recommended and bought more Todos. Best move I'll make this year. So to me, the declining share price is a gift since I'm still loading my already large position in Todos. And I promise I won't post here years afterwards blaming the CEO if my gamble doesn't work out. Unlike some, my maturity level for self reliance and responsibility actually progressed beyond my teenage years.
You're right. Lots of unsuspecting novice investors invested large sums with Gerald in Amarantus and lost it. Some continue to post about their woes.
Sad, but true.
If Gerald is a known serial liar and sociopath, what does that say about the investors who lost large sums with him as CEO of Amarantus? Were they gullible, not too bright, or did greed exceed their better judgement?
A sucker born every minute, eh?
IMHO, of course.
I doubled my position in Todos this past week. If I'd waited until the panic selling on Friday, I'd have gotten a better price. That's okay, I'll pick up some more shares this coming week. Price is still great considering where I expect we'll be when trial data is released. GLTA
CEO on Twitter - 11/5/21
The third thread posted here contains a number of responses after GC's tweet because I felt it was relevant to the discussion and these opinions might benefit readers. I normally only post GC's responses and any prior tweets leading to his response. If GC responds to these tweets I will include his responses in a later post.
Share Structure Update - 11/5/21
100,891 shares added this week.
https://www.otcmarkets.com/stock/TOMDF/security